Literature DB >> 28388736

Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?

María Reig1, Loreto Boix1, Zoe Mariño2, Ferran Torres3, Xavier Forns2, Jordi Bruix1.   

Abstract

The availability of new direct antiviral agents to safely and effectively treat the hepatitis C virus represents a major advancement in the field of liver disease. Most patients achieve complete viral eradication sustained over time. In addition, the administration of these new agents is safe and does not require limitations when liver function is impaired. Some now expect the hepatitis C virus to be completely eradicated in a few years. However, not all data are positive. In April 2016, we published a cohort study suggesting that viral eradication with the new agents could be associated in time with the emergence of recurrent cancer sites in patients previously treated for hepatocellular carcinoma. In this review, we update our report and summarize the data provided in recent publications. We also speculate about the mechanisms for cancer emergence and stress the need for further studies. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28388736     DOI: 10.1055/s-0037-1601349

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  22 in total

1.  Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy.

Authors:  N Saraiya; A C Yopp; N E Rich; M Odewole; N D Parikh; A G Singal
Journal:  Aliment Pharmacol Ther       Date:  2018-05-30       Impact factor: 8.171

Review 2.  Direct-acting antivirals for chronic hepatitis C.

Authors:  Janus C Jakobsen; Emil Eik Nielsen; Joshua Feinberg; Kiran Kumar Katakam; Kristina Fobian; Goran Hauser; Goran Poropat; Snezana Djurisic; Karl Heinz Weiss; Milica Bjelakovic; Goran Bjelakovic; Sarah Louise Klingenberg; Jian Ping Liu; Dimitrinka Nikolova; Ronald L Koretz; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2017-09-18

3.  Risk of De Novo Hepatocellular Carcinoma Following Use of Direct Acting Antiviral Medications for Treatment of Chronic Hepatitis C.

Authors:  Samuel O Antwi; Holly K Van Houten; Lindsey R Sangaralingham; Tushar Patel
Journal:  Cancer Prev Res (Phila)       Date:  2019-08-26

4.  De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era.

Authors:  Allison J Kwong; W Ray Kim; Jennifer A Flemming
Journal:  Hepatology       Date:  2018-10       Impact factor: 17.425

5.  Hepatocellular metastasis recurrence in liver transplant after treatment with direct antiviral agents.

Authors:  Silvia Maier; Debora Donnini; Laura De Luca; Claudio Avellini; Leonardo Alberto Sechi; Giorgio Soardo
Journal:  Clin J Gastroenterol       Date:  2019-08-13

Review 6.  AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.

Authors:  Amit G Singal; Joseph K Lim; Fasiha Kanwal
Journal:  Gastroenterology       Date:  2019-03-13       Impact factor: 22.682

7.  Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma.

Authors:  Amit G Singal; Nicole E Rich; Neil Mehta; Andrea D Branch; Anjana Pillai; Maarouf Hoteit; Michael Volk; Mobolaji Odewole; Steven Scaglione; Jennifer Guy; Adnan Said; Jordan J Feld; Binu V John; Catherine Frenette; Parvez Mantry; Amol S Rangnekar; Omobonike Oloruntoba; Michael Leise; Janice H Jou; Kalyan Ram Bhamidimarri; Laura Kulik; George N Ioannou; Annsa Huang; Tram Tran; Hrishikesh Samant; Renumathy Dhanasekaran; Andres Duarte-Rojo; Reena Salgia; Sheila Eswaran; Prasun Jalal; Avegail Flores; Sanjaya K Satapathy; Sofia Kagan; Purva Gopal; Robert Wong; Neehar D Parikh; Caitlin C Murphy
Journal:  Gastroenterology       Date:  2019-07-30       Impact factor: 22.682

8.  No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk.

Authors:  Elijah J Mun; Pamela Green; Kristin Berry; George N Ioannou
Journal:  Eur J Gastroenterol Hepatol       Date:  2019-01       Impact factor: 2.566

9.  Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.

Authors:  Amit G Singal; Nicole E Rich; Neil Mehta; Andrea Branch; Anjana Pillai; Maarouf Hoteit; Michael Volk; Mobolaji Odewole; Steven Scaglione; Jennifer Guy; Adnan Said; Jordan J Feld; Binu V John; Catherine Frenette; Parvez Mantry; Amol S Rangnekar; Omobonike Oloruntoba; Michael Leise; Janice H Jou; Kalyan Ram Bhamidimarri; Laura Kulik; Tram Tran; Hrishikesh Samant; Renumathy Dhanasekaran; Andres Duarte-Rojo; Reena Salgia; Sheila Eswaran; Prasun Jalal; Avegail Flores; Sanjaya K Satapathy; Robert Wong; Annsa Huang; Suresh Misra; Myron Schwartz; Robert Mitrani; Sasank Nakka; Wassim Noureddine; Chanda Ho; Venkata R Konjeti; Alexander Dao; Kevin Nelson; Kelly Delarosa; Usman Rahim; Meher Mavuram; Jesse J Xie; Caitlin C Murphy; Neehar D Parikh
Journal:  Gastroenterology       Date:  2019-01-18       Impact factor: 22.682

10.  HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection.

Authors:  Solomon Owusu Sekyere; Bernhard Schlevogt; Friederike Mettke; Mohammad Kabbani; Katja Deterding; Thomas Christian Wirth; Arndt Vogel; Michael Peter Manns; Christine Susanne Falk; Markus Cornberg; Heiner Wedemeyer
Journal:  Liver Cancer       Date:  2018-07-18       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.